证券代码：000950 证券简称：重药控股 公告编号：2025-043 重药控股股份有限公司 第九届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第九届董事会第十五次会议于 2025年7月10日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2025年7月1日以电子邮件和电话通知方式发出。会议应出席董事11人，实际出席 会议的董事11人。会议由公司董事长袁泉主持。本次会议的召开符合《公司法》 《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于修订<金融衍生品业务管理办法>的议案》 表决结果：同意11票，反对0票，弃权0票。 （二）审议通过《关于修订<担保管理办法>的议案》 （七）审议通过《关于制定<经理层成员任期制和契约化管理办法>的议案》 表决结果：同意11票，反对0票，弃权0票。 （三）审议通过《关于制定<利润分配管理办法>的议案》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 （四）审议通过《关于制定<内部控制管理规定>的 ...

Group 1 - The company expects a net profit attributable to shareholders of 260 million to 300 million yuan for the period from January 1, 2025, to June 30, 2025, representing a year-on-year growth of 9.2% to 26% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 250 million and 280 million yuan, indicating a year-on-year increase of 14.39% to 28.12% [1] - The basic earnings per share are estimated to be between 0.15 yuan and 0.17 yuan [1]

[Chongqing Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=2025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) This forecast outlines Chongqing Pharmaceutical Group's expected financial performance for the first half of 2025, projecting growth in key profitability metrics [I. Expected Performance for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) Chongqing Pharmaceutical Group anticipates year-over-year growth in net profit attributable to shareholders and net profit after deducting non-recurring gains and losses for H1 2025, alongside an increase in basic earnings per share [(I) Performance Forecast Period](index=1&type=section&id=(%E4%B8%80)%20%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%9C%9F%E9%97%B4) This section specifies the exact timeframe covered by the semi-annual performance forecast - The performance forecast covers the period from **January 1, 2025, to June 30, 2025**[2](index=2&type=chunk) [(II) Performance Forecast Details](index=1&type=section&id=(%E4%BA%8C)%20%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) This section presents the specific financial projections for the company's semi-annual performance - The company anticipates a **year-over-year increase** in its 2025 semi-annual performance[2](index=2&type=chunk) Key Financial Indicators for 2025 Semi-Annual Performance Forecast | Indicator | Estimated for Current Period (RMB 10,000) | Prior Year Same Period (RMB 10,000) | Year-over-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | 26,000 — 30,000 | 23,808.86 | 9.2% — 26% | | Net Profit After Deducting Non-Recurring Gains and Losses | 25,000 — 28,000 | 21,854.67 | 14.39% — 28.12% | | Basic Earnings Per Share (RMB/share) | 0.15 — 0.17 | 0.14 | - | [II. Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The financial data included in this performance forecast has not yet undergone pre-audit by a certified public accountant - The financial data related to this performance forecast has **not been pre-audited** by a certified public accountant[3](index=3&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's performance growth is primarily attributed to the implementation of its '14th Five-Year Plan' strategic initiatives, expanding diversified segmented businesses, optimizing network layout for revenue scale growth, and strengthening cost control to reduce operating and financing expenses - In line with its '14th Five-Year Plan' strategic initiatives, the company continues to develop diversified segmented businesses, including medical devices and reagents, traditional Chinese medicine health products, professional pharmacies, emerging businesses, and third-party reserves, building upon its core pharmaceutical sales[4](index=4&type=chunk) - Through both organic growth and external mergers and acquisitions, the company continuously **improves its network layout**, driving a corresponding **increase in revenue scale**[4](index=4&type=chunk) - The company has **strengthened cost control**, leading to a **significant reduction** in operating and administrative expenses and financing costs[4](index=4&type=chunk)[5](index=5&type=chunk) [IV. Other Related Information](index=2&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) This performance forecast represents preliminary estimates, with final financial data subject to the 2025 semi-annual report, and investors are advised to be aware of investment risks - This performance forecast is a **preliminary estimate** by the company, and the specific financial data will be fully disclosed in the company's 2025 semi-annual report[6](index=6&type=chunk) - Investors are kindly reminded to **exercise caution regarding investment risks**[6](index=6&type=chunk)

Group 1: Business Overview - The company primarily engages in pharmaceutical commerce, warehousing logistics, pharmaceutical manufacturing, and R&D, with pharmaceutical commerce as the core business. In 2024, the revenue distribution was 95.03% for wholesale and 4.59% for retail [2] - Revenue from pharmaceutical products and medical devices accounted for 82.11% and 15.82% respectively in 2024 [2] - The company is expanding into emerging business areas such as medical aesthetics, special medical foods, veterinary drugs, health products, and radioactive drugs [2] Group 2: Financial Performance - Financial costs decreased due to a declining trend in financing interest rates influenced by recent national monetary policies [3] - The company’s credit has improved since joining the General Technology Group, leading to a significant expansion of financing channels and a noticeable decline in financing costs since 2024 [3] Group 3: Business Collaboration - Since joining the General Technology Group, the company has accelerated collaboration with over 400 medical institutions, having opened accounts in 104 and initiated supply chain services in 93 [4] Group 4: Medical Device Sector - The medical device business includes a wide range of products such as medical devices, equipment, consumables, diagnostic reagents, IVD, and orthopedic products, with consumables being the largest category. The revenue from medical devices accounted for 15.82% in 2024 [5] Group 5: Retail Sector - The retail pharmacy segment includes community health pharmacies and DTP prescription pharmacies, with 776 community pharmacies and 181 DTP pharmacies covering 22 provinces and municipalities by the end of 2024. The retail segment's revenue accounted for 4.59% in 2024 [6] - The company plans to enhance its retail channel construction and develop a comprehensive marketing service network to provide diverse health services [6] Group 6: Market Value Management - The company places high importance on market value management and has recently disclosed a market value management system. Future plans include optimizing the equity structure and selecting suitable market value management tools to enhance investment value [7]

Group 1 - The core viewpoint of the article highlights that Zhongyao Holdings has made significant progress in sustainable development, achieving an upgrade in ESG rating from BB to A, moving from 71st to 8th among 114 healthcare providers and service companies [2] - In 2023, Zhongyao Holdings accelerated its collaborative development with the General Technology Group, enhancing its marketing and supply chain capabilities, and expanding its product matrix across 21 provinces with 102 new accounts, including 86 grade hospitals [2] - The company reported a revenue of 20.612 billion yuan in Q1, a year-on-year increase of 5.03%, and a net profit attributable to shareholders of 125 million yuan, up 21.63% year-on-year, with a basic earnings per share of 0.07 yuan [2] Group 2 - Looking ahead, Zhongyao Holdings emphasizes the integration of sustainable development into its corporate strategy, focusing on compliance, green low-carbon initiatives, and social contributions, aiming to create a win-win industrial ecosystem [3] - The company is committed to balancing economic and social benefits while enhancing its ESG governance model, with a mission to lead a better life through technological advancement and quality service [3]

Group 1 - The company, Zhongyao Holdings, is currently embroiled in litigation, with a total of approximately 1.164 billion yuan involved in lawsuits and arbitration over the past twelve months, which accounts for 10.28% of the company's latest audited net assets attributable to the parent company [1][2] - The company has seen continuous revenue growth from 2022 to 2024, with revenues of 67.829 billion yuan, 80.119 billion yuan, and 80.562 billion yuan respectively, marking a consistent increase [3] - However, the net profit attributable to the parent company has declined over the same period, with figures of 0.952 billion yuan, 0.625 billion yuan, and 0.283 billion yuan, reflecting a year-on-year decrease of 5.29%, 34.41%, and 54.69% respectively [3] Group 2 - The company has faced significant credit impairment losses, which were 0.104 billion yuan, 0.440 billion yuan, and 0.524 billion yuan from 2022 to 2024, indicating issues with accounts receivable collection [3] - Financial expenses have also impacted net profit, with expenses of 1.094 billion yuan, 1.302 billion yuan, and 1.084 billion yuan over the same period, highlighting substantial financial pressure [3] - As of the end of 2024, the company's debt ratio stood at 75.29%, with monetary funds of 9.392 billion yuan and interest-bearing liabilities of 23.189 billion yuan [3] Group 3 - The company has consistently distributed cash dividends from 2021 to 2024, with dividends of 0.183 billion yuan, 0.104 billion yuan, 0.0864 billion yuan, and 0.104 billion yuan, and dividend payout ratios of 18.21%, 10.89%, 13.19%, and 36.64% respectively [4] - In the first quarter of this year, the company reported a recovery in operating performance, with revenues and net profits attributable to the parent company of 20.612 billion yuan and 0.125 billion yuan, reflecting year-on-year growth of 5.03% and 21.63% [4] - As of July 2, the company's market capitalization was 8.641 billion yuan, with projected revenues exceeding 80 billion yuan for 2024 [5]

证券代码：000950 证券简称：重药控股 公告编号：2025-041 重药控股股份有限公司 关于累计诉讼、仲裁案件情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）根据《深圳证券交易所股票上市 规则》有关规定，对公司及控股子公司连续十二个月累计涉及诉讼、仲裁事项进 行了统计，现将有关统计情况公告如下： 一、累计诉讼、仲裁事项的基本情况 截止本公告披露日，公司及控股子公司连续十二个月内新增尚未披露的诉讼、 仲裁事项的涉案金额共计为 116,396.75 万元，涉案金额累计达公司最近一期经审 计归属于母公司净资产的 10.28%；其中公司及控股子公司作为原告的相关案件 金额共计为 95,845.79 万元。 具体情况详见《连续十二个月累计未披露诉讼、仲裁案件情况统计表》。 三、本次公告的诉讼、仲裁对公司本期利润或期后利润的可能影响 鉴于部分案件尚未开庭审理或者尚未结案，其对公司本期利润或期后利润的 影响存在不确定性，公司将依据会计准则的要求和案件实际情况进行相应的会计 处理，并按照《深圳证券交易所股票上市规则》要 ...

证券代码：000950 证券简称：重药控股 公告编号：2025-040 近日，重药控股股份有限公司（以下简称"公司"）控股子公司重庆医药（集 团）股份有限公司（以下简称"重药股份"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的《受理通知书》，现将有关情况公告如下： 一、药物基本信息 药物名称：盐酸普拉格雷片 剂型：片剂 申请事项：境内生产药品注册临床试验 受理号：CYHL2500119、CYHL2500120 申请人：重庆医药（集团）股份有限公司 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 重药控股股份有限公司 关于子公司药物临床试验获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 盐酸普拉格雷片原研公司为第一三共株式会社，是第三代的抑制 ADP 激活 的血小板聚集的药物，适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉 综合征、稳定型心绞痛，陈旧性心肌梗塞患者的血栓形成。目前已在全球 70 多 个国家和地区上市（中国境内未上市）。 重药股份投资引进第一三共株式会社的盐酸普拉格雷片技术及独家 ...

每经记者｜王琳 每经编辑｜董兴生 6月18日晚间，重药控股（000950.SZ，股价4.94元，市值85.37亿元）发布公告披露，其于6月18日收到公司控股股东重庆医药健康产业有限公司（以下简称 重庆医健）的告知函，获悉其股权结构拟发生变更。 具体来说，重庆医健的股东重庆渝富控股集团有限公司（以下简称重庆渝富）于6月18日在重庆联合产权交易所集团股份有限公司（以下简称重庆联交所） 公开挂牌转让重庆医健24%股权。 2024年全年，重庆医健实现营业收入和净利润分别为811.75亿元和4.14亿元；2025年第一季度，重庆医健的营业收入和净利润分别为207.57亿元和1.87亿元。 截至2025年一季度末，重庆医健的所有者权益为188.07亿元。 | | 以下数据出自年度审计报告 | | | | --- | --- | --- | --- | | 2024 (年度) | 营业收入 | 营业利润 | 浄利润 | | | 8117500. 21万元 | 57886. 30万元 | 41361. 24万元 | | | 资产总计 | 负债总计 | 所有者权益 | | | 6900556. 26万元 | 5042140.1 ...

关于控股股东股权结构拟发生变更的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）于 2025 年 6 月 18 日收到公司 控股股东重庆医药健康产业有限公司（以下简称"重庆医健"）的告知函，获悉 其股权结构拟发生变更。现就有关情况公告如下： 证券代码：000950 证券简称：重药控股 公告编号：2025-039 重药控股股份有限公司 一、基本情况概述 公司控股股东重庆医健的股东重庆渝富控股集团有限公司（以下简称"重庆 渝富"）于 2025 年 6 月 18 日在重庆联合产权交易所集团股份有限公司（以下简 称"重庆联交所"）公开挂牌转让重庆医健 24%股权。项目信息详见重庆联交所 网站（http://www.cquae.com/）。 重庆医药健康产业有限公司《告知函》。 重药控股股份有限公司董事会 2025 年 6 月 19 日 三、风险提示 重庆渝富公开挂牌转让重庆医健 24%股权是否能在公开征集期内征集到意 向投资方以及后续能否取得有权部门的批准尚存在不确定性。公司将根据上述事 项的进展情况，按照相关规定及 ...